{"id":14622,"date":"2015-05-07T20:10:11","date_gmt":"2015-05-07T10:10:11","guid":{"rendered":"https:\/\/haei.org\/?p=14622"},"modified":"2015-06-01T20:15:36","modified_gmt":"2015-06-01T10:15:36","slug":"prometic","status":"publish","type":"post","link":"https:\/\/haei.org\/prometic\/","title":{"rendered":"Prometic to develop C1-INH as its next plasma-derived drug candidate"},"content":{"rendered":"<p>ProMetic Life Sciences Inc. has selected C1-INH as its next plasma-derived drug candidate to be developed. The C1-INH protein is most commonly used for the treatment of HAE. The world market for HAE reached US$1.1billion in 2014 and has been growing at an average rate of 44% in the last three years, and analysts expect the market to exceed US$3 billion by 2020.<\/p>\n<p>ProMetic has successfully completed the bioprocess to isolate and purify C1-INH, and has scheduled scale-up and GMP production to occur during the second half of 2015. ProMetic anticipates commencement of C1-INH clinical trial work in H1 2016.<\/p>\n<p>\u201cAs anticipated, our manufacturing platform is demonstrating its ability to produce multiple high-value biopharmaceuticals simultaneously and at yield and purity levels superior to those commercially available\u201d, declared Mr. Pierre Laurin, President and CEO\u00a0of ProMetic. \u201cWe will be announcing other proteins in the coming months. Some of these will be developed and marketed with commercial partners and are already, as in the case of C1-INH, in partnering discussions\u201d, added Mr. Laurin.<\/p>\n<p><em>(Source: ProMetic)<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ProMetic Life Sciences Inc. has selected C1-INH as its next plasma-derived drug candidate to be developed. The C1-INH protein is most commonly used for the treatment of HAE. The world market for HAE reached US$1.1billion in 2014 and has been growing at an average rate of 44% in the last three years, and analysts expect [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Prometic to develop C1-INH as its next plasma-derived drug candidate - HAE International (HAEi)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/haei.org\/prometic\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prometic to develop C1-INH as its next plasma-derived drug candidate - HAE International (HAEi)\" \/>\n<meta property=\"og:description\" content=\"ProMetic Life Sciences Inc. has selected C1-INH as its next plasma-derived drug candidate to be developed. The C1-INH protein is most commonly used for the treatment of HAE. The world market for HAE reached US$1.1billion in 2014 and has been growing at an average rate of 44% in the last three years, and analysts expect [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/haei.org\/prometic\/\" \/>\n<meta property=\"og:site_name\" content=\"HAE International (HAEi)\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/haeinternational\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-05-07T10:10:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2015-06-01T10:15:36+00:00\" \/>\n<meta name=\"author\" content=\"Henrik Balle Boysen\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@haeday\" \/>\n<meta name=\"twitter:site\" content=\"@haeday\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Henrik Balle Boysen\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/haei.org\/prometic\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/haei.org\/prometic\/\"},\"author\":{\"name\":\"Henrik Balle Boysen\",\"@id\":\"https:\/\/haei.org\/#\/schema\/person\/025e1a441ffed388e4b45759960bbf35\"},\"headline\":\"Prometic to develop C1-INH as its next plasma-derived drug candidate\",\"datePublished\":\"2015-05-07T10:10:11+00:00\",\"dateModified\":\"2015-06-01T10:15:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/haei.org\/prometic\/\"},\"wordCount\":185,\"publisher\":{\"@id\":\"https:\/\/haei.org\/#organization\"},\"articleSection\":[\"HAEi News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/haei.org\/prometic\/\",\"url\":\"https:\/\/haei.org\/prometic\/\",\"name\":\"Prometic to develop C1-INH as its next plasma-derived drug candidate - HAE International (HAEi)\",\"isPartOf\":{\"@id\":\"https:\/\/haei.org\/#website\"},\"datePublished\":\"2015-05-07T10:10:11+00:00\",\"dateModified\":\"2015-06-01T10:15:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/haei.org\/prometic\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/haei.org\/prometic\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/haei.org\/prometic\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/haei.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prometic to develop C1-INH as its next plasma-derived drug candidate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/haei.org\/#website\",\"url\":\"https:\/\/haei.org\/\",\"name\":\"HAE International (HAEi)\",\"description\":\"HAE International (HAEi) is the global umbrella organization for the world\u2019s Hereditary Angioedema (HAE) patient groups.\",\"publisher\":{\"@id\":\"https:\/\/haei.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/haei.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/haei.org\/#organization\",\"name\":\"HAE International\",\"url\":\"https:\/\/haei.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/haei.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/haei.org\/wp-content\/uploads\/2018\/10\/logo.png\",\"contentUrl\":\"https:\/\/haei.org\/wp-content\/uploads\/2018\/10\/logo.png\",\"width\":162,\"height\":82,\"caption\":\"HAE International\"},\"image\":{\"@id\":\"https:\/\/haei.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/haeinternational\/\",\"https:\/\/x.com\/haeday\",\"https:\/\/www.linkedin.com\/company\/haei---international-patient-organization-for-c1-inhibitor-deficiencies\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/haei.org\/#\/schema\/person\/025e1a441ffed388e4b45759960bbf35\",\"name\":\"Henrik Balle Boysen\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/haei.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/4823f37a6c07106279cad7dc0d24e815?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/4823f37a6c07106279cad7dc0d24e815?s=96&d=mm&r=g\",\"caption\":\"Henrik Balle Boysen\"},\"url\":\"https:\/\/haei.org\/author\/boysen\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prometic to develop C1-INH as its next plasma-derived drug candidate - HAE International (HAEi)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/haei.org\/prometic\/","og_locale":"en_US","og_type":"article","og_title":"Prometic to develop C1-INH as its next plasma-derived drug candidate - HAE International (HAEi)","og_description":"ProMetic Life Sciences Inc. has selected C1-INH as its next plasma-derived drug candidate to be developed. The C1-INH protein is most commonly used for the treatment of HAE. The world market for HAE reached US$1.1billion in 2014 and has been growing at an average rate of 44% in the last three years, and analysts expect [&hellip;]","og_url":"https:\/\/haei.org\/prometic\/","og_site_name":"HAE International (HAEi)","article_publisher":"https:\/\/www.facebook.com\/haeinternational\/","article_published_time":"2015-05-07T10:10:11+00:00","article_modified_time":"2015-06-01T10:15:36+00:00","author":"Henrik Balle Boysen","twitter_card":"summary_large_image","twitter_creator":"@haeday","twitter_site":"@haeday","twitter_misc":{"Written by":"Henrik Balle Boysen","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/haei.org\/prometic\/#article","isPartOf":{"@id":"https:\/\/haei.org\/prometic\/"},"author":{"name":"Henrik Balle Boysen","@id":"https:\/\/haei.org\/#\/schema\/person\/025e1a441ffed388e4b45759960bbf35"},"headline":"Prometic to develop C1-INH as its next plasma-derived drug candidate","datePublished":"2015-05-07T10:10:11+00:00","dateModified":"2015-06-01T10:15:36+00:00","mainEntityOfPage":{"@id":"https:\/\/haei.org\/prometic\/"},"wordCount":185,"publisher":{"@id":"https:\/\/haei.org\/#organization"},"articleSection":["HAEi News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/haei.org\/prometic\/","url":"https:\/\/haei.org\/prometic\/","name":"Prometic to develop C1-INH as its next plasma-derived drug candidate - HAE International (HAEi)","isPartOf":{"@id":"https:\/\/haei.org\/#website"},"datePublished":"2015-05-07T10:10:11+00:00","dateModified":"2015-06-01T10:15:36+00:00","breadcrumb":{"@id":"https:\/\/haei.org\/prometic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/haei.org\/prometic\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/haei.org\/prometic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/haei.org\/"},{"@type":"ListItem","position":2,"name":"Prometic to develop C1-INH as its next plasma-derived drug candidate"}]},{"@type":"WebSite","@id":"https:\/\/haei.org\/#website","url":"https:\/\/haei.org\/","name":"HAE International (HAEi)","description":"HAE International (HAEi) is the global umbrella organization for the world\u2019s Hereditary Angioedema (HAE) patient groups.","publisher":{"@id":"https:\/\/haei.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/haei.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/haei.org\/#organization","name":"HAE International","url":"https:\/\/haei.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/haei.org\/#\/schema\/logo\/image\/","url":"https:\/\/haei.org\/wp-content\/uploads\/2018\/10\/logo.png","contentUrl":"https:\/\/haei.org\/wp-content\/uploads\/2018\/10\/logo.png","width":162,"height":82,"caption":"HAE International"},"image":{"@id":"https:\/\/haei.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/haeinternational\/","https:\/\/x.com\/haeday","https:\/\/www.linkedin.com\/company\/haei---international-patient-organization-for-c1-inhibitor-deficiencies\/"]},{"@type":"Person","@id":"https:\/\/haei.org\/#\/schema\/person\/025e1a441ffed388e4b45759960bbf35","name":"Henrik Balle Boysen","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/haei.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/4823f37a6c07106279cad7dc0d24e815?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4823f37a6c07106279cad7dc0d24e815?s=96&d=mm&r=g","caption":"Henrik Balle Boysen"},"url":"https:\/\/haei.org\/author\/boysen\/"}]}},"distributor_meta":false,"distributor_terms":false,"distributor_media":false,"distributor_original_site_name":"HAE International (HAEi)","distributor_original_site_url":"https:\/\/haei.org","push-errors":false,"_links":{"self":[{"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/posts\/14622"}],"collection":[{"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/comments?post=14622"}],"version-history":[{"count":0,"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/posts\/14622\/revisions"}],"wp:attachment":[{"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/media?parent=14622"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/categories?post=14622"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haei.org\/wp-json\/wp\/v2\/tags?post=14622"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}